Press coverage about NuVasive (NASDAQ:NUVA) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NuVasive earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned headlines about the medical device company an impact score of 45.6921054686736 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

Shares of NuVasive (NUVA) opened at 66.63 on Friday. The stock’s 50 day moving average price is $73.76 and its 200 day moving average price is $74.02. NuVasive has a one year low of $56.70 and a one year high of $81.68. The stock has a market capitalization of $3.39 billion, a PE ratio of 104.93 and a beta of 1.06.

NuVasive (NASDAQ:NUVA) last issued its quarterly earnings data on Thursday, July 27th. The medical device company reported $0.46 EPS for the quarter, beating the consensus estimate of $0.44 by $0.02. NuVasive had a return on equity of 13.04% and a net margin of 3.50%. The company had revenue of $260.60 million for the quarter, compared to analyst estimates of $261.95 million. During the same period last year, the company earned $0.40 earnings per share. NuVasive’s quarterly revenue was up 10.3% compared to the same quarter last year. Equities research analysts predict that NuVasive will post $2.00 EPS for the current fiscal year.

A number of research analysts recently issued reports on NUVA shares. Morgan Stanley reiterated an “equal weight” rating and set a $88.00 price objective (up from $84.00) on shares of NuVasive in a research note on Tuesday, July 25th. Cowen and Company reiterated an “outperform” rating and set a $90.00 price objective (up from $85.00) on shares of NuVasive in a research note on Wednesday, June 28th. Piper Jaffray Companies reiterated an “overweight” rating and set a $90.00 price objective on shares of NuVasive in a research note on Wednesday, July 5th. BidaskClub downgraded NuVasive from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Finally, Royal Bank Of Canada reiterated a “buy” rating and set a $76.00 price objective on shares of NuVasive in a research note on Monday, May 15th. Five research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. NuVasive has an average rating of “Buy” and a consensus target price of $81.18.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at

In other news, EVP Peter Michael Leddy purchased 7,850 shares of the stock in a transaction dated Tuesday, August 1st. The shares were purchased at an average cost of $63.88 per share, with a total value of $501,458.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.70% of the stock is currently owned by company insiders.

About NuVasive

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Insider Buying and Selling by Quarter for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with's FREE daily email newsletter.